Healthcare provider profile · identity verified

Kyle Brekke, DO

Internal Medicine · PORTLAND, OR · NPI 1063891059

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	418	135
Levothyroxine Sodium	Levothyroxine Sodium	347	104
Pantoprazole Sodium	Pantoprazole Sodium	297	100
Losartan Potassium	Losartan Potassium	296	87
Amlodipine Besylate	Amlodipine Besylate	285	93
Rosuvastatin Calcium	Rosuvastatin Calcium	252	73
Omeprazole	Omeprazole	203	71
Tamsulosin Hcl	Tamsulosin Hcl	203	65
Hydrochlorothiazide	Hydrochlorothiazide	177	52
Lisinopril	Lisinopril	171	59
Gabapentin	Gabapentin	160	43
Metoprolol Succinate	Metoprolol Succinate	155	52
Eliquis	Apixaban	137	32
Simvastatin	Simvastatin	124	41
Allopurinol	Allopurinol	123	36
Potassium Chloride	Potassium Chloride	121	47
Tramadol Hcl	Tramadol Hcl	120	24
Oxycodone Hcl	Oxycodone Hcl	107	18
Metformin Hcl Er	Metformin Hcl	105	34
Warfarin Sodium	Warfarin Sodium	101	31
Carvedilol	Carvedilol	99	30
Ozempic	Semaglutide	99	22
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	90	15
Alprazolam	Alprazolam	76	16
Albuterol Sulfate Hfa	Albuterol Sulfate	74	29
Trazodone Hcl	Trazodone Hcl	68	22
Metoprolol Tartrate	Metoprolol Tartrate	67	21
Sertraline Hcl	Sertraline Hcl	62	22
Olmesartan Medoxomil	Olmesartan Medoxomil	60	19
Finasteride	Finasteride	58	24
Meloxicam	Meloxicam	58	23
Spironolactone	Spironolactone	57	23
Metformin Hcl	Metformin Hcl	56	16
Jardiance	Empagliflozin	54	16
Lorazepam	Lorazepam	54	14
Celecoxib	Celecoxib	52	15
Mounjaro	Tirzepatide	51	suppressed
Xarelto	Rivaroxaban	51	16
Furosemide	Furosemide	50	23
Citalopram Hbr	Citalopram Hydrobromide	48	14
Clonazepam	Clonazepam	46	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	46	19
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	45	15
Nystatin	Nystatin	44	11
Pravastatin Sodium	Pravastatin Sodium	43	11
Montelukast Sodium	Montelukast Sodium	42	14
Famotidine	Famotidine	41	15
Atenolol	Atenolol	40	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	40	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	39	suppressed
Diazepam	Diazepam	39	suppressed
Mirtazapine	Mirtazapine	39	15
Bupropion Xl	Bupropion Hcl	38	15
Escitalopram Oxalate	Escitalopram Oxalate	37	12
Venlafaxine Hcl Er	Venlafaxine Hcl	37	suppressed
Buspirone Hcl	Buspirone Hcl	35	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	35	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	35	suppressed
Tizanidine Hcl	Tizanidine Hcl	34	suppressed
Ezetimibe	Ezetimibe	33	14
Trulicity	Dulaglutide	33	suppressed
Propranolol Hcl	Propranolol Hcl	32	suppressed
Testosterone Cypionate	Testosterone Cypionate	32	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	31	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	30	11
Clopidogrel	Clopidogrel Bisulfate	29	11
Duloxetine Hcl	Duloxetine Hcl	29	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	28	suppressed
Synthroid	Levothyroxine Sodium	28	suppressed
Temazepam	Temazepam	28	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	27	suppressed
Loperamide	Loperamide Hcl	27	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	27	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	25	suppressed
Estradiol	Estradiol	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	12
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Morphine Sulfate Er	Morphine Sulfate	24	suppressed
Alendronate Sodium	Alendronate Sodium	23	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	22	suppressed
Pregabalin	Pregabalin	21	suppressed
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	20	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Baclofen	Baclofen	18	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Prednisone	Prednisone	17	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	16	suppressed
Fluconazole	Fluconazole	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Torsemide	Torsemide	16	suppressed
Varenicline Tartrate	Varenicline Tartrate	16	suppressed
Colchicine	Colchicine	14	suppressed
Digoxin	Digoxin	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Methocarbamol	Methocarbamol	14	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Premarin	Estrogens, Conjugated	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Valsartan	Valsartan	14	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Incruse Ellipta	Umeclidinium Bromide	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Liothyronine Sodium	Liothyronine Sodium	13	suppressed
Methadone Hcl	Methadone Hcl	13	suppressed
Irbesartan	Irbesartan	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	11	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Indomethacin	Indomethacin	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error